Regeneron COVID-19 antibody drug trial partially halted over safety concern

Regeneron stated the partial halt does not impact other trials testing the antibody drug, including one that is testing it in hospitalized COVID-19 clients getting low quantities of oxygen, as the drugmaker said the risk-benefit for them stays appropriate. In trials evaluating the antibody drug in less extreme clients, it was shown to decrease infection levels and physician check outs..

Regeneron will pause enrollment of hospitalized COVID-19 clients receiving oxygen or ventilation in the trial..

More articles on pharmacy: Moderna on track to report initial vaccine information next monthGileads earnings increases by 17%, driven by remdesivir salesRegeneron states its COVID-19 antibody cocktail reveals pledge in mild to moderate cases.

Regenerons partial trial halt is the second setback that occured in a weeklong period related to antibody drugs. Eli Lilly said Oct. 26 that a trial testing its COVID-19 antibody drug in hospitalized COVID-19 clients was ended by the National Institute of Allergy and Infectious Diseases after finding it does not enhance healing times or survival rates. The trial had actually been stopped briefly Oct. 13 after an independent committee discovered a safety concern.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.

Maia Anderson –
Friday, October 30th, 2020
Print|Email.

The drugmaker stated an independent data keeping track of committee observed a “prospective safety signal and undesirable risk/benefit profile.” It didnt release any other information about the issue.

Check out Regenerons complete news release here..

Regeneron sent a demand Oct. 7 with the FDA for an emergency use authorization of the drug..

Regenerons partial trial halt is the second problem that took place in a weeklong duration related to antibody drugs. Eli Lilly said Oct. 26 that a trial screening its COVID-19 antibody drug in hospitalized COVID-19 clients was ended by the National Institute of Allergy and Infectious Diseases after discovering it does not improve healing times or survival rates. The trial had actually been paused Oct. 13 after an independent committee found a security issue. Eli Lilly likewise didnt launch specific details about the security issue..

Regeneron will halt evaluating its COVID-19 antibody drug in the sickest hospitalized patients after an independent board found a security issue, the drugmaker stated Oct. 30.